Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Businessweek Archives

A Cartilage Transfusion For Bad Knees

Developments to Watch


KNEE INJURIES ARE A notorious problem for athletes. About 650,000 people a year undergo arthroscopic surgery to repair damaged cartilage in their knees. Unfortunately, because cartilage tissue doesn't regenerate in the body, the benefit often lasts just a few years.

Now, researchers at Genzyme Tissue Repair Inc. in Cambridge, Mass., have a promising new treatment for knee damage: a process to grow a patient's own cartilage cells that can be reimplanted in a bad knee. In a two-part surgical procedure, cartilage cells are removed through a biopsy, cultured at Genzyme's lab, then injected back into the damaged portion of the knee through open-knee surgery. The cells are held in place by the periosteum--the membrane that covers bone surface. If the procedure works, the cells integrate into the surrounding tissue and mature in normal cartilage, restoring frictionless movement to the knee.

The operation has been successful in Sweden, where 14 of 16 patients who underwent the process reported "good to excellent" results. On Mar. 24, New England Patriots and Boston Bruins team doctor Bertram Zarins will perform the first procedure in the U.S. on an unnamed patient at Massachusetts General Hospital. By the end of the year, Genzyme hopes the operation will be available in six U.S. cities. The price: $10,000 for the cell culture, plus hospital costs of up to $20,000.EDITED BY EMILY SMITH

blog comments powered by Disqus